# DPC-681

| Cat. No.:          | HY-19400  |                |                      |  |
|--------------------|---|----------------|----------------------|--|
| CAS No.:           | 284661-68-3                                       |                |                      |  |
| Molecular Formula: | C <sub>35</sub> H <sub>48</sub> FN <sub>5</sub> O | <sub>5</sub> S |                      |  |
| Molecular Weight:  | 669.85  |                |                      |  |
| Target:            | HIV Protease; HIV                                 |                |                      |  |
| Pathway:           | Anti-infectio                                     | n; Metab       | olic Enzyme/Protease |  |
| Storage:           | Powder  | -20°C          | 3 years              |  |
|                    |   | 4°C            | 2 years              |  |
|                    | In solvent  | -80°C          | 2 years              |  |
|                    |   | -20°C          | 1 year               |  |

## SOLVENT & SOLUBILITY

|  |                              | Solvent Mass<br>Concentration | 1 mg      | 5 mg      | 10 mg      |
|--|------------------------------|-------------------------------|-----------|-----------|------------|
|  | Preparing<br>Stock Solutions | 1 mM                          | 1.4929 mL | 7.4644 mL | 14.9287 mL |
|  | 5 mM                         | 0.2986 mL                     | 1.4929 mL | 2.9857 mL |            |
|  |                              | 10 mM                         | 0.1493 mL | 0.7464 mL | 1.4929 mL  |

### BIOLOGICAL ACTIVITY

| Description               | DPC-681 is a potent and selective inhibitor of HIV protease with IC90s for wild-type HIV-1 of 4 to 40 nM.IC50 value: 4 - 40 nM [1]Target: HIV proteasein vitro: DPC 681 is extremely potent inhibitor of wild-type HIV-1. When all of the HIV-1 strains tested are considered, the average concentrations required for 90% inhibition of replication were 7.3 ± 3.4 for DPC 681. DPC 681 shows no loss in potency toward recombinant mutant HIVs with the D30N mutation and a fivefold or smaller loss in potency toward mutant variants with three to five amino acid substitutions. [1]in vivo: The total body clearance (CL) of DPC 681 in dogs was high (1.8 liter/h/kg) equaling hepatic blood flow for this species (1.8 liter/h/kg). After an oral dosing, the Cmax increased ninefold between the 10- and 30-mg/kg DPC 681 dose groups. Bioavailability also increased between the 10- and 30-mg/kg dose groups (18.3 and 78.1%, respectively). These data suggest that hepatic extraction (first-pass effect) can be saturated in the dog. [1] |
|---------------------------|---|
| IC <sub>50</sub> & Target | HIV-1   |

#### REFERENCES

# Product Data Sheet





[1]. Kaltenbach RF 3rd, et al. DPC 681 and DPC 684: potent, selective inhibitors of human immunodeficiency virus protease active against clinically relevant mutant variants. Antimicrob Agents Chemother. 2001 Nov;45(11):3021-8.

#### Caution: Product has not been fully validated for medical applications. For research use only.

 Tel: 609-228-6898
 Fax: 609-228-5909
 E-mail: tech@MedChemExpress.com

 Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA